Clinical trials
Completed Phase 2 trials in Norway
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
392 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 8 |
| 2002 | 7 |
| 2003 | 7 |
| 2004 | 19 |
| 2005 | 28 |
| 2006 | 22 |
| 2007 | 23 |
| 2008 | 32 |
| 2009 | 30 |
| 2010 | 18 |
| 2011 | 29 |
| 2012 | 15 |
| 2013 | 9 |
| 2014 | 18 |
| 2015 | 15 |
| 2016 | 15 |
| 2017 | 17 |
| 2018 | 17 |
| 2019 | 10 |
| 2020 | 12 |
| 2021 | 8 |
| 2022 | 10 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 392 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Oslo University Hospital | 29 |
| GlaxoSmithKline | 28 |
| Novartis Pharmaceuticals | 22 |
| AstraZeneca | 21 |
| Boehringer Ingelheim | 15 |
| Norwegian University of Science and Technology | 15 |
| Bristol-Myers Squibb | 14 |
| Bayer | 13 |
| Pfizer | 11 |
| Haukeland University Hospital | 9 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 16 |
| Neoplasms | 13 |
| Melanoma | 11 |
| Diabetes Mellitus | 10 |
| Carcinoma, Non-Small-Cell Lung | 9 |
| Diabetes Mellitus, Type 2 | 9 |
| Neoplasm Metastasis | 9 |
| Recurrence | 9 |
| Heart Failure | 8 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 8 |
Trials
Showing 1 to 25 of 392. Each trial links to its page on Pharma Observatory.
292 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.